| DC24010 |
Plpro-IN-6(PLpro inhibitor)
Featured
|
A potent, noncovalent SARS-CoV papain-like protease (PLpro) inhibitor with IC50 of 2.6 uM. |
|
| DC22706 |
BMY 45778
Featured
|
A potent, non-prostanoid prostacyclin partial agonist that potently inhibits human (IC50=35 nM), rabbit (IC50=136 nM) and rat (IC50=1.3 uM) platelet aggregation. |
|
| DC22815 |
K252a |
A potent, non-selective tyrosine protein kinase inhibitor for Trk family, CaMK and other phosphorylase kinases. |
|
| DC20615 |
A 834735 |
A potent, nonselective, brain penetrant, full agonist at both the central CB1 and peripheral CB2 receptors with Ki of 4.6 and 0.31 nM, respectively. |
|
| DC22899 |
MK-3577 |
A potent, oral active glucagon receptor antagonist blocking the glucagon effect for the treatment of T2DM. |
|
| DC23709 |
FXR-sHE modulator 57 |
A potent, orally active dual modulator of FXR and soluble epoxide hydrolase (sEH) that exertss partial FXR agonism (pEC50=7.7) and sEH inhibitory activity (pIC50=8.4). |
|
| DC23968 |
GAP-134 hydrochloride |
A potent, orally active gap-junction modifier. |
|
| DC23969 |
GAP-134 |
A potent, orally active gap-junction modifier. |
|
| DC20972 |
DS79182026 |
A potent, orally active hepcidin production inhibitor with IC50 of 39 nM, with low kinase inhibitory activity. |
|
| DC20694 |
ASP 9853 |
A potent, orally active iNOS inhibitor (IC50=10 nM, NO release DLD-1 cells) that prevents dimerization of iNOS, but has no effect on the expression or enzyme activity of iNOS. |
|
| DC22737 |
CP-346086
Featured
|
A potent, orally active microsomal triglyceride transfer protein (MTP) inhibitor that inhibits both human and rodent MTP with IC50 of 2 nM. |
|
| DC21627 |
SC-806 |
A potent, orally active p38 MAPK inhibitor with IC50 of 50 nM, significantly decreases incidence of
arthritis in mouse collagen-induced arthritis.. |
|
| DC21288 |
MK-8617
Featured
|
A potent, orally active pan-inhibitor of HIF prolyl hydroxylase (HIF-PHD) with IC50 of 1.0,1.0, and 14 nM for HIF-PHD1, 2, and 3, respectively. |
|
| DC22849 |
DSM 74 |
A potent, orally active PfDHODH inhibitor (IC50=0.3 uM) with antimalarial activity. |
|
| DC22704 |
SN79 |
A potent, orally active sigma receptor antaognist with Ki of 27 and 7 nM for σ1 and σ2, respectively. |
|
| DC22601 |
BMS-433796 |
A potent, orally active γ-secretase inhibitor with cell IC50 of 0.3 nM. |
|
| DC22853 |
IDN-7314 |
A potent, orally active, and irreversible pan-Caspase protease inhibitor with IC50 of <0.08 to 7 nM for inhibition of activated caspase 3, 6 and 8. |
|
| DC11893 |
Firibastat |
A potent, orally active, centrally acting aminopeptidase inhibitor, the prodrug of the specific and selective aminopeptidase A inhibitor EC33. |
|
| DC11629 |
NK1-IN-9 |
A potent, orally active, dual NK1 receptor antagonist (IC50=0.5 nM) and SERT inhibitor (IC50=5.2 nM). |
|
| DC11855 |
CHR 2863 |
A potent, orally available hydrophobic aminopeptidase inhibitor that structurally mimics the aminopeptidase inhibitor Tostedostat.. |
|
| DC20807 |
Gemopatrilat |
A potent, orally available, dual ACE-neutral endopeptidase (vasopeptidase) inhibitor with IC50 of 12 and 63 nM, respectively. |
|
| DC21396 |
Marizomib
Featured
|
A potent, orally bioactive 20S proteasome inhibitor with IC50 of 1.3 nM (inhibition of proteasomal chymotrypsin-like proteolytic activity). |
|
| DC22598 |
Rislenemdaz |
A potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively, with no off-target activity. |
|
| DC23970 |
SCH-563705 |
A potent, orally bioavailable dual CXCR2/CXCR1 receptor antagonist with IC50 of 1.3 nM and 7.3 nM, respectively. |
|
| DC11518 |
Cavosonstat
Featured
|
Cavosonstat is a potent, orally bioavailable inhibitor of S-nitrosoglutathione reductase (GSNOR) and CFTR modulator. |
|
| DC21541 |
PSI-421 |
A potent, orally bioavailable P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.. |
|
| DC24192 |
Dasatinib hydrochloride |
A potent, orally bioavailable, dual Src/Abl kinase inhibitor with IC50 of 0.5, 0.4, 0.5 and <1 nM for Src, Lck, Yes and Bcr-Abl, respectively. |
|
| DC11695 |
AT-IAP |
A potent, orally bioavailable, dual XIAP/cIAP1 inhibitor with EC50 of 5.1/0.32 nM, respectively. |
|
| DC11697 |
AM-1638 |
A potent, orally bioavailable, full agonist of GPR40/FFA1 with EC50 of 0.16 uM. |
|
| DC11860 |
FV-162 |
A potent, orally bioavailable, irreversible proteasome inhibitor with potent antimyeloma activity (IC50<60 nM). |
|
